TY - JOUR T1 - Latent Hypothyreosis as a Clinical Biomarker for Therapy Response Under Abiraterone Acetate Therapy JF - Anticancer Research JO - Anticancer Res SP - 307 LP - 311 VL - 34 IS - 1 AU - ISABEL HEIDEGGER AU - UDO NAGELE AU - ANDREAS PIRCHER AU - RENATE PICHLER AU - WOLFGANG HORNINGER AU - JASMIN BEKTIC Y1 - 2014/01/01 UR - http://ar.iiarjournals.org/content/34/1/307.abstract N2 - Background: Abiraterone acetate (AA) is a selective oral inhibitor of Steroid-17α-Hydroxylase, for patients with castration-resistant prostate cancer. Not all patients respond to therapy, however, there are no biomarkers predicting response to AA therapy. The aim of the present study was the identification of a biomarker for patients who are likely to respond to AA therapy. Patients and Methods: We measured thyroid parameters in a collective of 30 patients before and during AA therapy. For statistical analyses, paired and unpaired t-tests were used. Results: During AA therapy, responders developed a significant increase in thyroid stimulating hormone (TSH) compared to non-responders (p=0.03). In the subgroup of responders, 16 out of 21 patients (76.1%) had a significant increase in TSH level (p=0.001), suggesting that TSH increase is predictive of therapy response. Non-responders showed no change in TSH level during AA therapy. Conclusion: Hypothyreosis may serve as a simple predictive biomarker for therapy response under AA therapy. ER -